• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

    10/24/22 9:00:00 AM ET
    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto & Home Supply Stores
    Consumer Discretionary
    Get the next $ELAN alert in real time by email

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors.

    Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics.

    Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of automotive parts and accessories, and served on the Board of Directors of Kindred Biosciences (NASDAQ:KIN), a leading biopharmaceutical company for pets, until it was acquired by Elanco Animal Health (NYSE:ELAN). She serves on the Board of Advisors for Covington Capital Management and is a Partner at XFactor Ventures, a leading investor in women-founded startups. Ms. Liu was named one of Forbes 30 Under 30 (in 2016) and Fortune's 10 Most Promising Women Entrepreneurs (in 2015).

    "For the past 18 months, we have benefited from Nanxi's advice and guidance as a member of our Advisory Board, and we are pleased to now welcome her as a new member of the Board of Directors," said Joseph R. Shaposhnik, TCW Special Purpose Acquisition Corp. Chairman and CEO. "She is a highly successful technology entrepreneur and brings a unique perspective to the leaders of businesses and our impressive team of advisors and directors."

    TCW Special Purpose Acquisition Corp. intends to identify, merge with and take public a durable and predictable business well positioned to deliver superior revenue growth. Its management is associated with TCW's New America Premier business unit, which was established by Mr. Shaposhnik in 2015.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

    About TCW Special Purpose Acquisition Corp.

    TCW Special Purpose Acquisition Corp. (the "Company"), a Delaware corporation, is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a private company. The Company is sponsored by The TCW Group, Inc., a leading global investment management firm with approximately $220 billion of assets under management. For more information please visit www.tcwspac.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005377/en/

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN
    $PRTS
    $TSPQ
    $KIN

    CompanyDatePrice TargetRatingAnalyst
    Elanco Animal Health Incorporated
    $ELAN
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    6/26/2025Mkt Perform → Outperform
    William Blair
    CarParts.com Inc.
    $PRTS
    3/6/2025$3.00Hold → Buy
    Craig Hallum
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2024$18.00Buy
    UBS
    Elanco Animal Health Incorporated
    $ELAN
    12/2/2024$14.00Market Perform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    Elanco Animal Health Incorporated
    $ELAN
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    Elanco Animal Health Incorporated
    $ELAN
    12/19/2023$17.00Buy
    Jefferies
    More analyst ratings

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/11/25 5:13:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/7/25 4:21:21 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/26/24 5:05:35 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CarParts.com Reports Second Quarter 2025 Results

    TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the second quarter ended June 28, 2025.  Second Quarter 2025 Summary vs. Year-Ago Quarter Net sales increased 5% to $151.9 million.Gross profit of $49.8 million vs. $48.4 million, with gross margin of 32.8%.Net loss was ($12.7) million, or ($0.23) per share, compared to a net loss of ($8.7) million, or ($0.15) per share.Adjusted EBITDA of (

    8/12/25 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs

    The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the worldLaunch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission. This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a signific

    7/24/25 5:42:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    SEC Filings

    View All

    SEC Form 10-Q filed by CarParts.com Inc.

    10-Q - CarParts.com, Inc. (0001378950) (Filer)

    8/12/25 4:37:17 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    CarParts.com Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CarParts.com, Inc. (0001378950) (Filer)

    8/12/25 4:14:14 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    SEC Form 144 filed by Elanco Animal Health Incorporated

    144 - Elanco Animal Health Inc (0001739104) (Subject)

    8/11/25 3:58:15 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:55:46 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:54:06 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/29/25 4:24:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Elanco Animal Health from Market Perform to Outperform and set a new price target of $18.00

    7/17/25 7:51:30 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by William Blair

    William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform

    6/26/25 7:49:03 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CarParts.com upgraded by Craig Hallum with a new price target

    Craig Hallum upgraded CarParts.com from Hold to Buy and set a new price target of $3.00

    3/6/25 8:20:37 AM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

    GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

    5/28/25 7:25:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Strengthens Board of Directors with Addition of Stacey Ma

    Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

    11/12/24 8:33:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Financials

    Live finance-specific insights

    View All

    CarParts.com Reports Second Quarter 2025 Results

    TORRANCE, Calif., Aug. 12, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the second quarter ended June 28, 2025.  Second Quarter 2025 Summary vs. Year-Ago Quarter Net sales increased 5% to $151.9 million.Gross profit of $49.8 million vs. $48.4 million, with gross margin of 32.8%.Net loss was ($12.7) million, or ($0.23) per share, compared to a net loss of ($8.7) million, or ($0.15) per share.Adjusted EBITDA of (

    8/12/25 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CarParts.com Sets Second Quarter 2025 Conference Call for Tuesday, August 12, 2025

    TORRANCE, Calif., July 22, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) will hold a conference call on Tuesday, August 12, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the second quarter ended June 28, 2025. The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and CFO Ryan Lockwood will host the conference call live via an audio webcast. The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the webcast will be archived on the

    7/22/25 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/12/24 1:35:28 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/4/24 10:24:21 AM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    9/10/24 12:09:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary